Plasmacytoid bladder cancer is an aggressive histologic variant with a high risk of disease-specific mortality. Using wholeexome and targeted sequencing, we find that truncating somatic alterations in the CDH1 gene occur in 84% of plasmacytoid carcinomas and are specific to this histologic variant. Consistent with the aggressive clinical behavior of plasmacytoid carcinomas, which frequently recur locally, CRISPR/Cas9-mediated knockout of CDH1 in bladder cancer cells enhanced cell migration.
b r i e f c o m m u n i c a t i o n s
Plasmacytoid bladder cancer is an aggressive histologic variant with a high risk of disease-specific mortality. Using wholeexome and targeted sequencing, we find that truncating somatic alterations in the CDH1 gene occur in 84% of plasmacytoid carcinomas and are specific to this histologic variant. Consistent with the aggressive clinical behavior of plasmacytoid carcinomas, which frequently recur locally, CRISPR/Cas9-mediated knockout of CDH1 in bladder cancer cells enhanced cell migration.
Bladder cancer is the ninth most common cancer worldwide and the fourth most common cancer in men 1 . Cancers arising in the urothelial tract display a wide spectrum of variant morphologies, and, stage for stage, tumors composed of purely variant histologies tend to have worse survival. All variant bladder cancer histologies were excluded from The Cancer Genome Atlas (TCGA) 2, 3 , and the molecular basis for the morphologic and prognostic heterogeneity of bladder cancers remains ill-defined. To explore whether the morphologic heterogeneity of urothelial tumors has an underlying molecular basis, we characterized the mutational landscape of plasmacytoid urothelial carcinoma, a histologic variant with an aggressive clinical course marked by advanced stage at presentation, chemotherapy resistance, frequent local recurrence and a peritoneal pattern of spread [4] [5] [6] [7] .
Six plasmacytoid variant bladder tumors were initially analyzed by whole-exome sequencing, and all six harbored nonsense mutations in CDH1, the gene encoding E-cadherin (Supplementary Fig. 1 ). In contrast, no CDH1-truncating mutations were detected in 127 bladder tumors in the TCGA cohort comprising urothelial carcinoma, not otherwise specified (NOS). To further confirm the association between CDH1 mutation and plasmacytoid variant bladder cancer, we performed targeted exon capture and sequencing of 19 additional plasmacytoid variant bladder tumors (Fig. 1a and Supplementary Table 1), 14 (74%) of which harbored CDH1 mutations. We also performed a centralized histologic review of the first 62 patients with invasive bladder cancer prospectively sequenced as part of their clinical care. In this prospective cohort, CDH1 mutations were identified in six patients, all of whose tumors exhibited the plasmacytoid variant histology, whereas no CDH1 alterations were observed in the 56 nonplasmacytoid variant samples (Fig. 1a) . With the exception of CDH1 alterations, the genomic profile of plasmacytoid variant tumors was not substantially different from that of the 183 urothelial carcinoma, NOS, tumors in the TCGA or Memorial Sloan Kettering prospective cohort, with frequent mutations in the tumor suppressors TP53 and RB1, the chromatin remodeler ARID1A, and the targetable kinases ERBB2 and PIK3CA (Fig. 1a,b) .
Plasmacytoid variant tumors consist of malignant epithelial cells with eccentrically located nuclei growing in a diffuse, discohesive pattern with minimal stromal reaction. These tumors have also been referred to as diffuse or signet ring cell carcinomas. Notably, this morphologic appearance has similarities with those of lobular breast carcinoma and diffuse gastric carcinoma, both of which frequently harbor CDH1 mutations 8, 9 (Fig. 1c) . In contrast to the germline point mutations in CDH1 that typify diffuse hereditary gastric cancers, we identified no germline CDH1 alterations in the plasmacytoid variant bladder cancers. The co-mutation patterns of lobular breast and diffuse gastric cancers were also distinct from that of plasmacytoid variant bladder carcinoma with the exception of CDH1 alterations (Supplementary Fig. 2) .
Variant morphologies often coexist with urothelial carcinoma, NOS, in patients with invasive bladder cancer. To explore whether the plasmacytoid variant and urothelial carcinoma, NOS, components in such tumors evolve from a shared cell of origin, we performed exon capture and deep sequencing of two adjacent portions of a bladder tumor that contained distinct regions of plasmacytoid variant and urothelial carcinoma, NOS, histology (Supplementary Fig. 3 ). Both histologic regions had mutations in CDKN1A (p.Ala45Glyfs*3) and PIK3C2G (p.Ser48Arg), implying that these were truncal alterations occurring in a common precursor cell. A CDH1 mutation encoding p.Ser70Profs*13 alongside mutations in PTEN, NOTCH2, FAT4 and other genes were, however, unique to the plasmacytoid component.
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To confirm that the CDH1 alterations identified in the plasmacytoid variant tumors resulted in loss of protein expression, we performed immunohistochemistry for E-cadherin. All 31 plasmacytoid tumors from the whole-exome sequencing, validation and prospective cohorts exhibited loss of E-cadherin expression, including five tumors with wild-type CDH1. As CDH1 promoter hypermethylation is an alternative mechanism of E-cadherin loss in other cancer types [10] [11] [12] , we performed bisulfite sequencing of the CDH1 promoter CpG island. CDH1 promoter hypermethylation was present in four of the five plasmacytoid tumors with wild-type CDH1 but in none of the CDH1-mutant or urothelial carcinoma, NOS, specimens examined ( Supplementary Fig. 4) . Notably, E-cadherin staining was absent in the invasive component of plasmacytoid variant tumors but was retained within in situ regions (Supplementary Fig. 5 ). In sum, the results indicate that loss of E-cadherin expression, most commonly as a result of somatic CDH1 mutation, is the defining molecular event in plasmacytoid variant bladder cancers.
Patients with plasmacytoid variant bladder cancers displayed a higher cumulative incidence of local recurrence and cancer-specific mortality (Fig. 2a,b) and more often exhibited a pattern of peritoneal spread than patients with bladder tumors with pure urothelial carcinoma, NOS, histology (Supplementary Data Set). To explore whether E-cadherin loss is the molecular basis for the distinct pattern of local invasion observed in patients with plasmacytoid variant bladder cancers, we performed CRISPR/Cas9-mediated knockout of CDH1 in two urothelial carcinoma cell lines (RT4 and MGHU4) ( Fig. 2c and Online Methods). Loss of E-cadherin expression resulted in increased migratory capability of MGHU4 cells in an in vitro wound-healing assay (Fig. 2d,e) , and both RT4 and MGHU4 CDH1-knockout lines displayed enhanced migration across a Boyden chamber membrane as compared to the parental lines (Fig. 2f) . These results suggest that somatic loss-of-function mutations in CDH1, with consequent E-cadherin loss, lead to the enhanced cellular migration and invasive properties characteristic of plasmacytoid variant tumors. 
In summary, we report CDH1 alteration as the pathognomonic feature of plasmacytoid variant bladder cancer, a disease subtype with an aggressive clinical behavior and poor prognosis. Loss of E-cadherin expression, as a result of CDH1 somatic mutation or promoter hypermethylation, is associated with enhanced cellular migration, likely explaining the unique peritoneal pattern of disease dissemination and poor clinical outcome of patients with this disease. Although inactivating mutations in CDH1 were found exclusively in plasmacytoid variant tumors, the pattern of co-altered genes was similar to that of bladder cancers with uniformly urothelial carcinoma, NOS, histology. This suggests that both histologic subtypes likely evolve from a common cell of origin, with CDH1 alterations demarcating a distinct evolutionary path. The frequent presence of clinically actionable alterations in genes such as ERBB2, PIK3CA and TSC1 and the poor prognosis of patients with this disease imply that early use of targeted agents, as part of a multimodality treatment approach, should be considered for patients with plasmacytoid variant bladder cancers.
URLs. cBioPortal, http://www.cbioportal.org/.
MethodS
Methods and any associated references are available in the online version of the paper.
Accession codes. Whole-exome sequencing data from tumor and matched germline samples have been deposited in the database of Genotypes and Phenotypes (dbGaP) under accession phs001064.v1.p1. Clinical data analysis. Clinical data were accessioned for 53 patients treated at Memorial Sloan Kettering Cancer Center between July 1994 and April 2014 who had tumors of predominantly plasmacytoid histology. Among this group, 16 patients had metastases at presentation and were excluded from recurrence and survival analyses. Two patients had treatment and follow-up at outside hospitals and also were excluded, leaving 37 patients who were included in the survival analyses. Information on patient demographics, pathological stage, surgical margin status, clinical follow-up and use of preoperative chemotherapy in a neoadjuvant or consolidative setting was obtained. The same clinicopathological data were collected for 978 patients who received definitive treatment for pure bladder urothelial carcinoma between May 2001 and March 2010. The median follow-up time among survivors was 71.8 months (minimum = 0.4 months, maximum = 150 months). During follow-up, 437 patients died. Of those deaths, 270 were due to cancer. There were 348 recurrences during follow-up, of which 170 were local recurrences. Baseline characteristics were compared by histology, using Fisher's exact test for categorical factors and the Wilcoxon test for continuous factors. Follow-up time started at the date of radical cystectomy or the completion of definitive treatment. Because many patients died of causes other than cancer and because many patients died without recurrence, we used competing events methods when calculating cancer-specific mortality and local recurrence-free survival. Cumulative incidence estimated cancer-specific mortality and local recurrence-free survival, and Gray's test was used to compare groups. Multivariable survival analyses were conducted using Cox regression or competing risks regression.
A P value <0.05 was considered to be statistically significant. All analyses were conducted in R software version 3.1.1 (R Core Development Team).
Whole-exome sequencing. Four formalin-fixed, paraffin-embedded and two frozen tumors with matched normal tissue underwent DNA extraction with the DNeasy Blood and Tissue kit (Qiagen) following the manufacturer's instructions. These six samples were subjected to whole-exome sequencing. Between 1.5 and 2 µg of genomic DNA was captured by hybridization using SureSelect XT Human All Exon V4 (Agilent Technologies). Samples were prepared according to the manufacturer's instructions. PCR amplification of the libraries was carried out for six cycles in the precapture step and for ten cycles after capture. Samples were barcoded and run on a HiSeq 2500 instrument in 100-bp paired-end runs using TruSeq SBS kit v5 (Illumina). The average number of read pairs per sample was 63 million, the average duplication rate was 12% and 94.4% of the targeted regions were sequenced at 30× or higher coverage.
Sequence alignment and mutation identification. Sequence alignment and mutation identification were performed as previously described 13 . Briefly, paired-end sequencing data from exome capture libraries were aligned to the reference human genome (hg19) using the Burrows-Wheeler Aligner 14 . Deduplication, base quality recalibration and multiple-sequence realignment were performed using the Picard suite and the Genome Analysis Toolkit before mutation detection 15, 16 . BAM files were coordinate sorted and processed for both point mutations and small indels less than 50 bp in length. Singlenucleotide variants were detected with MuTect, a Bayesian framework for the detection of somatic mutations, and indels were detected using Pindel 17, 18 .
Targeted exon and capture sequencing. A solution-phase hybridizationbased exon capture and massively parallel DNA sequencing assay was used to determine the mutation and copy number alteration profiles of 300 cancerassociated genes in 25 plasmacytoid variant tumor samples as previously described 19 . Six additional plasmacytoid variant tumors were subjected to a CLIA-certified assay (Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets, or MSK-IMPACT) that screens 341 cancerassociated genes using the same technology 20 . Exon capture sequencing data were deposited in the cBioPortal for Cancer Genomics 21 .
Bisulfite sequencing. Genomic DNA (500 ng) was modified with sodium bisulfite using the EZ DNA Methylation-Lightning kit (Zymo Research). PCR primers were used to amplify a 259-bp fragment from a CpG island beginning 311 bp upstream of the CDH1 translation start site (Supplementary Table 2 ). The PCR product was then subcloned into the pSC-A-amp PCR cloning vector (Agilent Technologies) according to the manufacturer's instructions for Sanger sequencing. Bisulfite conversion efficiency was calculated by dividing the number of non-CpG cytosines converted to thymines by the total number of non-CpG cytosines, and clones with conversion efficiencies less than 95% were not analyzed. Data analysis was performed using BISMA 22 .
CRISPR/Cas9-mediated knockout of CDH1. The LentiCRISPR v2 plasmid deposited by Sanjana et al. 23 was obtained from Addgene, and a mutation encoding p.Asp10Ala was introduced in the Cas9 coding sequence to improve the specificity of genome editing. Oligonucleotides targeting exon 3 of CDH1 were subcloned into LentiCRISPR v2 nickase (Supplementary Table 2 ). Lentivirus was produced by transfecting these two constructs together with psPAX2 and pMD2.G (Addgene) into HEK293T cells, and RT4 and MGHU4 bladder cancer cells (gifts from M. Knowles, University of Leeds) were infected. Single clones of transduced cells were screened for E-cadherin expression by immunoblot analysis (antibody to E-cadherin from Cell Signaling Technology, 3195; 1:1,000 dilution), and those without detectable E-cadherin protein were used to perform further experiments. The cell lines were not tested for mycoplasma.
Wound-healing assays. MGHU4 and MGHU4 CDH1-knockout clones were plated on a 60-mm dish in MEM with 10% FBS and allowed to divide to create a confluent monolayer. The medium was changed to MEM with 2% FBS 8 h before the wound-healing assay was performed. The monolayer was scratched with a P200 pipet tip, cell debris was removed by washing once with MEM with 2% FBS, and the cells were cultured in MEM with 2% FBS. Image acquisition was performed immediately after scratching and at 16 and 20 h after scratching. Images were analyzed using the Microscope Image Analysis Toolbox (MiToBo) extension for ImageJ.
Boyden chamber cell migration assays. Each assay experiment was conducted in a 24-well plate. Cells (5 × 10 4 ) were seeded in the upper chamber of a Transwell chamber insert (8.0 µm), and medium containing 10% FBS and 20 ng/ml epidermal growth factor (EGF) was placed outside the insert to serve as a chemoattractant. After a 24-h incubation period, migrated cells were fixed
